Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01047839 · ClinicalTrials.gov registry record · Phase 3
Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries
A Phase 3 study, sponsored by Valneva Austria.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT01047839 is a Phase 3 study that has completed, run by Valneva Austria. The registered enrollment target is 100 participants.
The verdict
NCT01047839, a Phase 3 study, has completed, sponsored by Valneva Austria.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
The primary objective is to assess the safety profile of IC51 in a pediatric population from regions where JEV is not endemic
Interventions
- BIOLOGICAL IC51
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01047839
The ClinicalTrials.gov registry entry for NCT01047839 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Valneva Austria, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IC51 is the first listed.
NCT01047839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01047839 about?
NCT01047839 is a clinical study titled "Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries". The primary objective is to assess the safety profile of IC51 in a pediatric population from regions where JEV is not endemic
What is the current status of trial NCT01047839?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2010-01. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01047839?
The interventions under investigation include: IC51 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01047839?
This trial is sponsored by Valneva Austria, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.